Study Data from Castle Biosciences' Collaboration with the National Cancer Institute's SEER Program Registries Published in JCO Precision OncologyBusiness Wire • 06/30/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Castle Biosciences, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 06/26/23
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Castle Biosciences, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 06/21/23
Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Castle BioSciences, Inc. (CSTL)Business Wire • 06/16/23
CASTLE ALERT: Bragar Eagel & Squire, P.C. is Investigating Castle Biosciences, Inc. on Behalf of Castle Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 06/16/23
Castle Biosciences Presents New Data Demonstrating the Ability of DecisionDx®-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional StagingBusiness Wire • 06/12/23
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Castle Biosciences, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 06/10/23
Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Castle Biosciences, Inc. (CSTL)Business Wire • 06/09/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Castle Biosciences, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 06/09/23
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Castle Biosciences, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire • 06/06/23
Framework Incorporating DecisionDx®-SCC Test Results into Clinical Decision-Making for Patients with High-Risk Cutaneous Squamous Cell Carcinoma Published in Clinical, Cosmetic and Investigational DermatologyBusiness Wire • 06/05/23
Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual MeetingBusiness Wire • 06/03/23
IDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive DisorderBusiness Wire • 05/31/23
Castle Biosciences' Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as “Posters of Distinction” by the American Gastroenterological Association (AGA) Institute CouncilBusiness Wire • 05/26/23
Castle Biosciences' TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence InnovationBusiness Wire • 05/15/23
Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging StudiesBusiness Wire • 05/03/23
Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling EventBusiness Wire • 04/28/23
DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma PatientsBusiness Wire • 04/25/23
TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett's Esophagus Patients with Low-Grade DysplasiaBusiness Wire • 04/20/23
